

Effects of Vitamin K₃ and K₅ on Daunorubicin-resistant Human T Lymphoblastoid Leukemia Cells

ERI NAKAOKA, SACHIKO TANAKA, KENJI ONDA, KENTARO SUGIYAMA and TOSHIHIKO HIRANO

*Department of Clinical Pharmacology, School of Pharmacy,
Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan*

Abstract. *Background/Aim:* Anticancer efficacy of vitamin K derivatives on multidrug-resistant cancer cells has been scarcely investigated. *Materials and Methods:* The effects of vitamins K₃ and K₅ on proliferation of human leukemia MOLT-4 cells and on daunorubicin-resistant MOLT-4/DNR cells were estimated by a WST assay. Apoptotic cells were detected by Annexin V and propidium iodide staining, followed by flow cytometry. *Results:* Vitamins K₃ and K₅ significantly inhibited proliferation of leukemic cells at 10 and 100 μM ($p < 0.05$), and these effects were almost equally observed in both MOLT-4 and MOLT-4/DNR drug-resistant cells. Vitamin K₃ induced cell apoptosis at 10 and 100 μM in both MOLT-4 and MOLT-4/DNR cells ($p < 0.05$). Vitamin K₅ also increased apoptotic cells, while rather inducing necrotic cell death. *Conclusion:* Vitamins K₃ and K₅ suppress MOLT-4 and MOLT-4/DNR cell-proliferation partially through induction of apoptosis, and these vitamin derivatives can overcome drug resistance due to P-glycoprotein expression.

There have been a number of reports concerning anticancer properties of lipophilic vitamins, which include, differentiation-inducing efficacy of tretinoin against clinical promyelocytic leukemia (1), the anti-proliferative and apoptosis-inducing efficacy of vitamin D3 in breast cancer and colorectal cancer (2), and the apoptosis-inducing and chemosensitivity-enhancing effects of vitamin E succinate in bladder cancer cells (3). We also found apoptosis-inducing effects of vitamin K derivatives on human melanoma cells (4). In addition, the antitumor effects of vitamin K₂ (menaquinone), K₃ (menadione), and K₅ (4-amino-2-methyl-

1-naphthol) against colorectal cancer (5) and hepatocellular carcinoma (6) models have also been demonstrated. Vitamin K₂ and K₃ were shown to possess apoptosis-inducing effects in human tumorigenic cells (5, 7). Vitamin K₂, K₃, and K₅ exerted antitumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells (5).

Thus, while vitamin K derivatives have been known to induce apoptotic cell death in several types of cancer cells, their effects on drug-resistant cancer cells have not been clarified. The success of chemotherapy in cancer treatment is frequently limited by intrinsic or acquired multidrug resistance due to increased expression of a plasma membrane P-glycoprotein (8). This protein is an ATP-dependent transporter that effluxes a number of structurally-unrelated anticancer agents out of cells, thereby reducing intracellular drug concentration, permitting cancer cells to survive against high concentrations of anticancer drugs. We developed multidrug-resistant cell line MOLT-4/DNR from a human T lymphoblastoid leukemia MOLT-4 cell line by exposing parent cells to increasing concentrations of daunorubicin over 3 months (9). This resistant sub-line, MOLT-4/DNR has been revealed to overexpress functional P-glycoprotein and *MDR1* mRNA (9). Moreover, drug resistance in MOLT-4/DNR has been shown to be closely related to the expression of P-glycoprotein and *MDR1* mRNA (9), and therefore, this sub-line will be a suitable model to investigate the agents which overcome drug resistance due to functional P-glycoprotein expression.

The present study was undertaken to evaluate anti-proliferative effects of vitamin K derivatives, K₃ and K₅, on a P-glycoprotein-expressing multidrug-resistant cell line MOLT-4/DNR, and to provide an insight into their mechanisms of action by examining apoptotic cells treated with the vitamin K derivatives.

Materials and Methods

Reagents. RPMI-1640 medium and fetal bovine serum were purchased from Gibco BRL Co. (Grand Island, NY, USA). Daunorubicin, vitamin K₃ and K₅ were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Daunorubicin stock solutions were prepared at a concentration of 10 mmol/L with ethanol and

Correspondence to: Toshihiko Hirano, Ph.D., Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan. Tel: +81 42676-5794, Fax: +81 426765798, e-mail: hiranot@toyaku.ac.jp

Key Words: Vitamin K₃, vitamin K₅, human T-lymphoblastoid leukemia, daunorubicin resistance, P-glycoprotein, apoptosis.

diluted to working concentrations before use. Test-compound solutions were made at a concentration of 5 mmol/L with ethanol and diluted to working concentrations before use. Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Laboratories (Kumamoto, Japan). FITC Annexin V Apoptosis Detection Kit I was obtained from BD Biosciences (Pharmingen, CA, USA). All other reagents were of the best available grade.

Cell culture and cell proliferation assay. MOLT-4 cells were purchased from DS PharmaBiomedical Co., Ltd. (Osaka, Japan). Human breast cancer cell line MCF-7 was obtained from Riken BRC Co. (Ibaraki, Japan). MOLT-4/DNR cells have been developed from MOLT-4 cell line by exposing the parent cells to increasing concentrations stepwise of daunorubicin over 3 months (9). MOLT-4 and MOLT-4/DNR cells were maintained in RPMI-1640 medium containing 10% fetal bovine serum, 100 units/mL penicillin and 100 µg/ml streptomycin (9, 10).

The leukemia cells were washed and re-suspended with the above medium to 5×10^5 cells/mL, and 196 µL of this cell suspension were placed in each well of a 96 well flat-bottom plate. Four micro litters of ethanol solution containing each vitamin K derivative or 4 µl of ethanol solution containing daunorubicin were added to yield final concentrations of 0.001, 0.01, 0.1, 1, 10 and 100 µM, respectively. Four micro litters of ethanol were added to the control wells. The cell suspensions were mixed and incubated for 72 h in 5% CO₂/air at 37°C.

MCF-7 cells were maintained in MEMα medium containing 10% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin (11). The cells at densities of $1-5 \times 10^5$ cells/ml suspended with each medium were incubated in 5% CO₂/air at 37°C for 3-4 days in a humidified chamber. The cells were washed and re-suspended with the medium to 5×10^5 cells/ml, and 196 µL of this cell suspension were placed in each well of a 96 well flat-bottom plate. Four micro litters of ethanol solution containing each vitamin K derivative were added to yield final concentrations of 0.1, 1, 10 and 100 µM, respectively. Four micro litters of ethanol were added to the control wells. The cell suspensions were mixed and incubated for 72 h in 5% CO₂/air at 37°C.

Cell proliferation was analyzed with a WST assay using Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) according to the manufacture's instructions. After culturing, 20 µL of Cell Counting Kit-8 reagent solution was added to each well, and the plate was incubated for another 2 h. Then, the proliferated cells were analyzed by measuring the optical density at 450 nm absorbance (reference, 650 nm).

Apoptosis assays. After 5×10^5 cells/mL of MOLT-4 and MOLT-4/DNR cell suspensions were incubated in the presence of indicated concentrations of vitamin K₃ or K₅ for 72 h in 5%CO₂/air at 37°C. One ml of this cell suspension was placed in a 1.5-mL tube, and the cells were washed twice in cold phosphate-buffered saline (pH 7.2). Cells were re-suspended with 500 µL of phosphate-buffered saline containing 1% fetal bovine serum, and 5 µL of Annexin V-FITC solution and 2.5 µL of propidium iodide solution (50 µg/mL) were added to the tube. Then, the cells were incubated for 15 min at room temperature in the dark. After the incubation, 400 µL of binding buffer were added to each tube, and the cells were analyzed by flow cytometry (BD FACSCalibur™, BD Biosciences) within one hour after staining (12). A total of 30,000 non-gated cells were analyzed. Apoptotic cells were detected as Annexin V-positive and propidium iodide-negative cells, while necrotic cells were detected as Annexin V and propidium iodide double-positive cells.

Statistics. Comparison of the data between the two groups was carried out by Student's *t*-test. Comparison of the data in multiple groups was carried-out by the Dunnett test. In each case, *p*-values less than 0.05 were considered significant.

Results

Effects of vitamin K₃ and K₅ on proliferation of MOLT-4 and drug-resistant MOLT-4/DNR cells. Daunorubicin dose-dependently suppressed proliferation of MOLT-4 cells, while the drug was less effective on MOLT-4/DNR cell proliferation (Figure 1A). The difference in the daunorubicin effect on cell proliferation between MOLT-4 cells and MOLT-4/DNR cells was statistically significant at a drug concentration of 1 µM (*p*<0.05). The IC₅₀ value of daunorubicin on proliferation of MOLT-4/DNR cells was 15.5-times higher than that of the drug on the proliferation of MOLT-4 cells. Daunorubicin treatment at 0.1 and 10 µM significantly increased the number of apoptotic cells in MOLT-4 cells, compared to the number of apoptotic cells in the drug-resistant MOLT-4/DNR cells (*p*<0.05) (Figure 1B).

Then, cells of the parental MOLT-4 and the drug-resistant MOLT-4/DNR cell lines were continuously treated with 0.1 to 100 µM of vitamin K₃ and K₅ for 72 h, and cell proliferation was assessed by WST assay procedures (Figure 2A and B). Vitamins K₃ and K₅ inhibited the proliferation of these cells at a concentration range of 10-100 µM. In contrast to the effects of daunorubicin, proliferation of MOLT-4 and MOLT-4/DNR cells were suppressed almost equally by the vitamin K derivatives, K₃ and K₅, in a dose-dependent manner. The effects of these vitamins on MOLT-4 and MOLT-4/DNR cell proliferation were not significantly different at any concentrations used in this study. Anti-proliferative effects of vitamins K₃ and K₅ were also examined using human breast cancer cell line MCF-7 (Figure 2C). Both vitamin K derivatives inhibited MCF-7 cell proliferation dose-dependently, whereas the effects on this cell line were somewhat weaker compared to the effects on the leukemia cell lines.

Then, the additive effects of vitamin K₃ combined with daunorubicin were examined using MOLT-4 and MOLT-4/DNR cells (Figure 3). The daunorubicin dose-response curves to suppress proliferation of these cells appeared to be unchanged in the absence or presence of 0.1 and 1 µM vitamin K₃. As described above, MOLT-4/DNR cells, compared to parental MOLT-4 cells, showed resistance to the suppressive effects of daunorubicin (Figure 3B). The daunorubicin IC₅₀ values on MOLT-4/DNR cell proliferation were more than ten-times higher than those on the parent MOLT-4 cell proliferation, even in the presence of 0.1 and 1 µM vitamin K₃. However, the dose-response curves of daunorubicin on the proliferation of MOLT-4 (Figure 3A) and MOLT-4/DNR cells (Figure 3B) were almost the same in the presence of 10 µM vitamin K₃. The IC₅₀ values of daunorubicin in the presence




Figure 1. Different daunorubicin responses in cells of the parent MOLT-4 and the drug-resistant MOLT-4/DNR cell lines. A: Cells of the parent MOLT-4 (open circle) and the drug-resistant MOLT-4/DNR (closed circle) cell lines were cultured in presence of serial concentrations of daunorubicin for 72 h, and cell proliferation was analyzed by WST assay procedures. B: MOLT-4 (open circle) and MOLT-4/DNR (closed circle) cells were treated with serial concentrations of daunorubicin, stained with Annexin V and propidium iodide, and analyzed with flow cytometry. Apoptotic cells were detected as Annexin V-positive and propidium iodide-negative cells (see also Figure 4A-D). Experiments were carried-out three times, and the differences in the percentages of apoptotic cells between the two cells lines were analyzed by unpaired *t*-tests. **p*<0.05 between the two cell lines.

of 10 μM vitamin K₃ on the proliferation of MOLT-4 and MOLT-4/DNR cells were less than 10 μM.

Apoptosis induction in MOLT-4 and drug-resistant MOLT-4/DNR cells by vitamin K₃ and K₅ treatment. Parental MOLT-4 and the drug-resistant MOLT-4/DNR cell lines were cultured in presence of vitamin K₃ or K₅ at concentrations of 0.1, 1.0, 10, and 100 μM for 48 h, stained with Annexin V and




Figure 2. Effects of vitamins K₃ and K₅ on *in vitro* proliferation of MOLT-4 cells, MOLT-4/DNR cells, and MCF-7 cells. Cells were treated with serial concentrations of vitamin K derivatives for 72 h, and cell proliferation was estimated by WST assay. A, B: Effects of vitamin K₃ (A) and K₅ (B) on MOLT-4 (open circle) and MOLT-4/DNR (closed circle) cells. No statistically significant differences were observed in the vitamin K effects between MOLT-4 and MOLT-4/DNR cells. C: Effects of vitamin K₃ (open triangle) and K₅ (closed triangle) on MCF-7 cells.

propidium iodide, and the percentages of apoptotic cells in an Annexin V-positive and PI-negative area were estimated (Figure 4; lower right area in each right figure). Typical dot plot data of apoptotic cells treated by vitamin K derivatives and analyzed with flow cytometry are shown in Figure 4A-D. Number of apoptotic cells increased in both MOLT-4 and MOLT-4/DNR cells after the treatment by vitamin K₃, especially in cells treated by 10 and 100 μM of vitamin K₃. The mean percentages of apoptotic cells in MOLT-4 and MOLT-4/DNR cells treated with 0.1-100 μM vitamin K₃ or K₅ are also shown in Figures 4E and F. These vitamin K derivatives increased the number of apoptotic cells in both MOLT-4 and MOLT-4/DNR cells, and the effects of vitamin K₃ at 10 and 100 μM were statistically significant, compared to control ($p < 0.001$) (Figure 4E). The effect of vitamin K₃ at 1 μM on MOLT-4 cells was also statistically significant ($p < 0.05$) (Figure 4E). When compared to the effects of vitamin K₃, vitamin K₅ by 10 and 100 μM tended to cause necrotic cells in both MOLT-4 and MOLT-4/DNR cells, as can be seen in the right upper area (Annexin V and propidium iodide double-positive cells) of each right-side Figure. Differences in inducing apoptotic cells and necrotic cells between vitamin K₃ or K₅ can be also seen in Figure 4E and F.

Discussion

The data described above show that vitamins K₃ and K₅ inhibit growth of both T lymphoblastoid leukemia MOLT-4 cells and P-glycoprotein-expressing daunorubicin-resistant MOLT-4/DNR cells almost equally. Vitamins K₃ and K₅ also inhibited proliferation of cells of a breast cancer cell line MCF-7. However, the vitamin K effects on this cell line were somewhat weaker, when compared to the effects of vitamin K derivatives on T lymphoblastoid leukemia cells. The anti-proliferative effects of vitamin K₃ and K₅ on leukemic cells were apparent at a concentration range of 10-100 μM, that was almost the same as the concentration range of these vitamin K derivatives exhibiting apoptosis induction. These observations suggest that the anti-proliferative effects of the vitamin K derivatives are partially due to apoptotic-cell induction in these cell lines. The apoptosis-inducing ability of vitamin K₃ was relatively stronger than that of vitamin K₅. Whereas, vitamin K₅ suggested to cause necrotic cell death, as can be seen in Figure 4E and F.

In the present study, we revealed that the IC₅₀ value of daunorubicin on the proliferation of MOLT-4/DNR cells was approximately 15.5-times higher than that of the drug on the proliferation of MOLT-4 cells. MOLT-4/DNR cell line was shown to be persistently resistant to the anti-proliferative effect of daunorubicin by expressing functional P-glycoprotein (9). Multidrug resistance is recognized as one of the most common causes for failure of chemotherapy in

treating cancer patients (8). P-glycoprotein is an ABC transporter, which hydrolyses ATP and extrudes cytotoxic drugs from mammalian cells. Herein, we found that both parental MOLT-4 and daunorubicin-resistant MOLT-4/DNR cells were sensitive to the suppressive effects of the vitamin K derivatives, and the effects were suggested to be additive in combination with daunorubicin. Moreover, the vitamin K derivatives especially vitamin K₃ induced apoptosis in both MOLT-4 and MOLT-4/DNR cells at concentrations higher than 1 μM. Thus, current data suggest that vitamin K₃ or K₅ are not excluded from the drug-resistant leukemia cells by P-glycoprotein, and are possible candidates for overcoming multidrug resistance in leukemia cells expressing functional P-glycoprotein.

We have reported in our previous study that vitamin K₃ and K₅ suppress *in vitro* growth of human melanoma A375 cells at concentrations lower than 10 μmol/L, which are suggested to results from apoptosis-induction in the melanoma cells (4). We also found that vitamins K₃ and K₅ diminished T cell immunity by inhibiting the proliferative response and inducing apoptosis in mitogen-activated human peripheral-blood lymphocytes (13). The antitumor effects of vitamin K₂ (menatetrenone), K₃, and K₅ against colorectal cancer (2) and hepatocellular carcinoma (6) models have been reported. Moreover, vitamin K₂ and K₃ have been shown to have apoptosis-inducing effects in human tumorigenic cells (5, 7). Vitamin K₂ was reported to induce apoptosis in a cell line established from a patient with myelodysplastic syndrome in blastic transformation (14), while vitamins K₂, K₃, and K₅ exerted anti-tumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells (5). Shah *et al.* reported that ubiquitin ligase inhibition by vitamin K₂ attenuates hypoxia and Ras/mitogen-activated protein kinase (MAPK) signaling, which results in blockade of melanoma tumorigenesis (15). On the other hand, Chowdhury *et al.* suggested that vitamin K₂ enhanced arsenic-induced apoptosis in melanoma cells through generation of reactive oxygen species, p38 signaling, and activation of p53 (16). Thus, blockade of these signaling cascades in combination is suggested to be part of the underlying mechanisms of anti-tumor effects of vitamin K derivatives.

The present study, in conclusion, showed that vitamin K₃ and K₅ suppress cell proliferation of both MOLT-4 and MOLT-4/DNR cells by inducing apoptosis, and that these vitamin derivatives can overcome drug resistance due to functional P-glycoprotein expression.

Conflicts of Interest

The Authors declare that there exist no conflicts of interest with regard to this study.




Figure 3. Dose-response curves of daunorubicin in combination with serial concentrations of vitamin K₃ against the proliferation of MOLT-4 (A) and MOLT-4/DNR (B) cells. In each case, cells were treated with serial concentrations of daunorubicin in the absence (0 μM) or presence of 0.1-10 μM vitamin K₃ for 72 h, and cell proliferation was estimated by WST assay procedures.

References

- Komura N, Ikeda Y, Masuda N, Umezawa Y, Ito K, Kizaki M and Umezawa K: Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor. *Leuk Res* 31: 301-313, 2007.
- Leysens C, Verlinden L and Verstuyf A: Antineoplastic effects of 1,25(OH)₂D₃ and its analogs in breast, prostate and colorectal cancer. *Endocr Relat Cancer* 20: R31-47, 2013.
- Kanai K, Kikuchi E, Mikami S, Suzuki E, Uchida Y, Kodaira K, Miyajima A, Ohigashi T, Nakashima J, and Oya M: Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells *in vitro* and *in vivo*. *Cancer Sci* 101: 216-223, 2010.
- Ishibashi M, Arai M, Tanaka S, Onda K and Hirano T: Antiproliferative and apoptosis-inducing effects of lipophilic vitamins on human melanoma A375 cells *in vitro*. *Biol Pharm Bull* 35: 10-17, 2011.
- Ogawa M, Nakai S, Deguchi A, Nonomura T, Masaki T, Uchida N, Yoshiji H and Kuriyama S: Vitamins K₂, K₃ and K₅ exert antitumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells. *Int J Oncol* 31: 323-331, 2007
- Kuriyama S, Hitomi M, Yoshiji H, Nonomura T, Tsujimoto T, Mitoro A, Akahane T, Ogawa M, Nakai S, Deguchi A, Masaki T and Uchida N: Vitamins K₂, K₃ and K₅ exert *in vivo* antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. *Int J Oncol* 27: 505-511, 2005.
- Akiyoshi T, Matzno S, Sakai M, Okamura N and Matsuyama K: The potential of vitamin K₃ as an anticancer agent against breast cancer that acts *via* the mitochondria-related apoptotic pathway. *Cancer Chemother Pharmacol* 65: 143-150, 2009.
- Luqmani YA: Mechanisms of drug resistance in cancer chemotherapy. *Med Princ Pract* 14(Suppl 1): 35-48, 2015.
- Liu ZL, Onda K, Tanaka S, Toma T, Hirano T and Oka K: Induction of multidrug resistance in MOLT-4 cells by anti-cancer




Figure 4. Continued.




Figure 4. Apoptotic cell induction by vitamin K derivatives in MOLT-4 and MOLT-4/DNR cells. Cells were treated with serial concentrations of vitamin K derivatives for 48 h, stained with Annexin V and propidium iodide, and analyzed with flow cytometry. Apoptotic cells were detected as Annexin V-positive and propidium iodide-negative cells, as shown in the lower-right area in each right-side figure (arrow in Figure A and B). A-D: Dot-plot analysis of apoptotic. The total cells shown in the left in each figure were gated as indicated by the surrounded area, and the cells in this area were analyzed as Annexin V-positive and propidium iodide-negative (apoptotic) cells (right-side in each Figure). Typical dot-plots were shown in each case. A and B: Effects of vitamin K₃ on MOLT-4 cells (left columns) and MOLT-4/DNR cells (right columns). C and D: Effects of vitamin K₅ on MOLT-4 cells (left columns) and MOLT-4/DNR cells (right columns). E and F: Mean percentages of apoptotic cells (left columns; open bars) and necrotic cells (right columns; closed bars) in MOLT-4 and MOLT-4/DNR cells after treatment by vitamin K₃ (E) and vitamin K₅ (F). The percentages of necrotic cells were calculated from the upper right area (Annexin V and propidium iodide double positive cells) in the dot plot data (insets A-D). Experiments were carried out for 5 times independently, and the differences in the percentages of apoptotic cells or necrotic cells treated by vitamin K derivatives, as compared to control (0 µM), were analyzed by Dunnett test. **p*<0.05, ***p*<0.01.

- agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. *Cancer Chemother Pharmacol* 49: 391-397, 2002.
- 10 Ishii K, Tanaka S, Kagami K, Henmi K, Toyoda H, Kaise T and Hirano T: Effects of naturally occurring polymethoxyflavonoids on cell growth, P-glycoprotein function, cell cycle, and apoptosis of daunorubicin-resistant T lymphoblastoid leukemia cells. *Cancer Invest* 28: 220-229, 2010.
 - 11 Yokoyama H, Ebara M, Nakamura F, Nanasawa A, Tanaka S, Onda K, Sugiyama K, Kasuya K, Muhetaer G, Shimazu M and Hirano T: Rapid and simple analysis of N-aspartylchlorin e6 (talaporfin) using fluorescence microtiterplate and its application for determination in cells, tissues and blood. *J Cancer Ther* 3: 521-527, 2012.
 - 12 Sakai C, Arai M, Tanaka S, Onda K, Sugiyama K and Hirano T: Effects of arsenic compounds on growth, cell-cycle, and apoptosis of tretinoin-resistant human promyelocytic leukemia cells. *Anticancer Res* 35: 6489-6494, 2014.
 - 13 Hatanaka H, Ishizawa H, Nakamura Y, Tadokoro H, Tanaka S, Onda K, Sugiyama K and Hirano T: Effects of vitamin K₃ and K₅ on proliferation, cytokine production, and regulatory T cell-frequency in human peripheral-blood mononuclear cells. *Life Sci* 99: 61-68, 2014. (10.1016/j.lfs.2014.01.068).
 - 14 Nishimaki J, Miyazawa K, Yaguchi M, Katagiri T, Kawanishi Y, Toyama K, Ohyashiki K, Hashimoto S, Nakaya K and Takiguchi T: Vitamin K₂ induces apoptosis of a novel cell line established from a patient with myelodysplastic syndrome in blastic transformation. *Leukemia* 13: 1399-1405, 1999.
 - 15 Shah M, Stebbins JL, Dewing A, Qi J, Pellicchia M and Ronai ZA: Inhibition of Siah2 ubiquitin ligase by vitamin K₃ (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis. *Pigment Cell Melanoma Res* 22: 799-808, 2009.
 - 16 Chowdhury R, Chowdhury S, Roychoudhury P, Mandal C and Chaudhuri K: Arsenic induced apoptosis in malignant melanoma cells is enhanced by menadione through ROS generation, p38 signaling and p53 activation. *Apoptosis* 14: 108-123, 2009.

Received July 7, 2015

Revised August 13, 2015

Accepted August 18, 2015